2016 Fiscal Year Final Research Report
Development of new therapeutic approaches against chronic liver diseases with combination of hepatic progenitor cells and clinical available agents
| Project/Area Number |
26461017
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 肝線維化 / 肝再生 / 肝前駆細胞 |
|---|
| Outline of Final Research Achievements |
During the period of this grant, we revealed many new findings about the usefulness of the combined cocktail therapy with hepatic progenitor cells (HPC) and clinical available agents such as angiotensin II receptor blocker (ARB) in several types of animal models of liver fibrosis development and hepatocarcinogenesis. Even at clinical comparable low doses of these agents, we observed significant inhibitory effects on the liver fibrosis development, hepatocarcinogenesis, and the growth of hepatocellular carcinoma (HCC) with many publications in international journals. Furthermore, we observed that specific NOTCH-1 inhibitor significantly suppressed the liver fibrosis development along with augmentation of hepatic regeneration. It is well known that augmentation of liver regeneration would play a pivotal role for improvement of hepatic reserve. Collectively, our studies with this grant could contribute to the improvement of prognosis in patients with chronic liver diseases.
|
| Free Research Field |
肝臓学
|
